BridgeBio Pharma, Inc. (BBIO) insider trading.
In Q3 2026, insiders at BridgeBio Pharma, Inc. reported 24 non-derivative transactions on 8 Forms 3, 4 and 5: 0 open-market purchases and 13 sales worth $19.2M.
- Transactions
- 24
- Purchases (P)
- 0
- Sales (S)
- 13
- Net shares, P minus S
- -222,736
- Insiders
- 5
- Last filed
- 2026-09-21
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Kumar Neil | Director, Officer · Chief Executive Officer | 14 | 0 | 9 |
| Cook Jennifer E. | Director | 5 | 0 | 2 |
| Apuli Maricel | Officer · Chief Accounting Officer | 2 | 0 | 1 |
| Ellis Andrea | Director | 2 | 0 | 1 |
| Trimarchi Thomas | Officer · President and CFO | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-17 | Kumar Neil | S (D) | 1,279 | $69.57 | 495,686 | Form 4 |
| 2026-09-17 | Kumar Neil | S (D) | 8,721 | $69.01 | 496,965 | Form 4 |
| 2026-08-19 | Kumar Neil | S (D) | 100 | $85.65 | 505,686 | Form 4 |
| 2026-08-19 | Kumar Neil | S (D) | 1,800 | $84.69 | 505,786 | Form 4 |
| 2026-08-19 | Kumar Neil | S (D) | 8,100 | $83.86 | 507,586 | Form 4 |
| 2026-08-18 | Kumar Neil | S (D) | 14,602 | $82.99 | 244,526 | Form 4 |
| 2026-08-18 | Kumar Neil | S (D) | 1,900 | $81.15 | 276,407 | Form 4 |
| 2026-08-18 | Kumar Neil | S (D) | 17,279 | $82.21 | 259,128 | Form 4 |
| 2026-08-18 | Kumar Neil | S (D) | 1,199 | $83.77 | 243,327 | Form 4 |
| 2026-08-16 | Apuli Maricel | F (D) | 4,714 | $79.86 | 122,687 | Form 4 |
| 2026-08-16 | Kumar Neil | F (D) | 36,237 | $79.86 | 278,307 | Form 4 |
| 2026-08-16 | Kumar Neil | M (A) | 6,520 | — | 314,544 | Form 4 |
| 2026-08-16 | Kumar Neil | M (A) | 19,599 | — | 296,470 | Form 4 |
| 2026-08-16 | Kumar Neil | M (A) | 33,544 | — | 276,871 | Form 4 |
| 2026-08-16 | Kumar Neil | M (A) | 11,554 | — | 308,024 | Form 4 |
| 2026-08-16 | Trimarchi Thomas | F (D) | 22,781 | $79.86 | 336,529 | Form 4 |
| 2026-07-30 | Apuli Maricel | S (D) | 2,000 | $80.06 | 127,401 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | S (D) | 36,167 | $84 | 120,805 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | M (A) | 17,167 | $16.75 | 156,972 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | M (A) | 112,422 | $29 | 139,805 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | M (A) | 19,000 | $8.45 | 27,383 | Form 4 |
| 2026-07-09 | Cook Jennifer E. | S (D) | 112,422 | $90 | 8,383 | Form 4 |
| 2026-07-09 | Ellis Andrea | S (D) | 17,167 | $84 | 22,579 | Form 4 |
| 2026-07-09 | Ellis Andrea | M (A) | 17,167 | $16.75 | 39,746 | Form 4 |
Transaction codes in this quarter
Get BBIO insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1743881&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · BBIO company page · BridgeBio Pharma, Inc. on SEC.gov
Questions
Are insiders buying or selling BridgeBio Pharma, Inc. (BBIO)?
In Q3 2026, insiders at BridgeBio Pharma, Inc. reported 24 non-derivative transactions on 8 Forms 3, 4 and 5: 0 open-market purchases and 13 sales worth $19.2M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these BridgeBio Pharma, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/bbio.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.